Citation | Ye, XY; Chen, SY; Wu, S; Yoon, DS; Wang, H; Hong, Z; O'Connor, SP; Li, J; Li, JJ; Kennedy, LJ; Walker, SJ; Nayeem, A; Sheriff, S; Camac, DM; Ramamurthy, V; Morin, PE; Zebo, R; Taylor, JR; Morgan, NN; Ponticiello, RP; Harrity, T; Apedo, A; Golla, R; Seethala, R; Wang, M; Harper, TW; Sleczka, BG; He, B; Kirby, M; Leahy, DK; Li, J; Hanson, RL; Guo, Z; Li, YX; DiMarco, JD; Scaringe, R; Maxwell, B; Moulin, F; Barrish, JC; Gordon, DA; Robl, JA Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem60:4932-4948 (2017) [PubMed] Article |
---|
SMILES | Fc1ccc(cc1)C1(CC(=O)N2CC(F)(F)C2)C2CC3CC(C2)CC1C3 |TLB:8:7:18.25.19:23.21.22,4:7:22:18.19.20,25:24:22:18.19.20,THB:8:7:22:18.19.20,4:7:18.25.19:23.21.22,25:19:7.24.23:22,20:19:7:23.21.22,20:21:7:18.25.19,(23.41,-40.89,;23.42,-39.35,;22.1,-38.56,;22.11,-37.02,;23.46,-36.27,;24.78,-37.04,;24.77,-38.58,;23.47,-34.73,;22.33,-33.7,;20.87,-34.18,;19.61,-33.26,;20.38,-35.64,;19,-36.34,;19.7,-37.71,;20.09,-39.2,;18.61,-38.81,;21.08,-37.01,;24.67,-33.45,;26,-33.94,;27.4,-33.6,;27.42,-32.07,;26.01,-31.49,;24.67,-31.97,;24.97,-32.73,;24.97,-34.32,;26.39,-34.88,)| |